8-K: CG Oncology Unveils Strong Bladder Cancer Data

CG Oncology presented updated corporate data highlighting cretostimogene's best-in-disease durability and safety in bladder cancer.

Summary

• Cretostimogene grenadenorepvec, an oncolytic immunotherapy, demonstrates a dual mechanism of action for selective tumor killing and durable anti-tumor immune response.
• In the Phase 3 BOND-003 Cohort C for HR BCG-unresponsive NMIBC CIS, cretostimogene showed a 12-month Complete Response (CR) rate of 46.4% and a 24-month CR rate of 41.8%.
• The estimated Duration of Response (DoR) was 64.2% at 12 months and 60.1% at 24 months, with a median DoR exceeding 28 months and ongoing.
• 96.6% of all treated patients were free from progression to Muscle Invasive Bladder Cancer (MIBC) at 24 months, and 83.6% of responders avoided radical cystectomy by Month 24.
• Promising early results from BOND-003 Cohort P in HR BCG-unresponsive NMIBC Ta/T1 showed a 90.5% High-Grade Recurrence-Free Survival (HG-RFS) at both 3 and 9 months.
• Cretostimogene exhibited a favorable safety profile with 0% Grade 3+ treatment-related adverse events (TRAEs) and a median time to AE resolution within 1 day.
• The treatment is designed for easy administration by a qualified healthcare professional in a regular clinic room, fitting existing practice workflows.
• CG Oncology has comprehensive programs targeting High-Risk and Intermediate-Risk NMIBC, addressing over 70% of the multi-billion dollar NMIBC market opportunity.
• The company's cash runway is expected to extend into the first half of 2028.

Sentiment

Score: 9

Explanation: The presentation highlights exceptionally strong efficacy and safety data for cretostimogene, particularly its best-in-disease durability and lack of severe adverse events, positioning it favorably against competitors in a large market with significant unmet need. The company also has a strong cash runway and clear development path.

Positives

• Demonstrated best-in-disease durability with a median Duration of Response (DoR) exceeding 28 months and ongoing, outperforming comparable therapies.
• Achieved a high 24-month Complete Response (CR) rate of 41.8% in HR BCG-unresponsive NMIBC CIS, superior to other approved drugs.
• Exhibited an excellent safety profile with 0% Grade 3+ treatment-related adverse events (TRAEs) and a median time to AE resolution of just 1 day.
• High rate of patients (96.6% at 24 months) free from progression to Muscle Invasive Bladder Cancer (MIBC) and 83.6% of responders avoiding radical cystectomy.
• Promising early efficacy signal in HR BCG-unresponsive NMIBC Ta/T1 with 90.5% HG-RFS at 3and 9-month, comparing favorably to benchmarks of 43-55% DFS at 12-month.
• Cretostimogene has received both Breakthrough Therapy and Fast Track designations, indicating regulatory recognition of its potential.
• The treatment is minimally invasive and can be easily prepared and administered in a standard clinic setting, enhancing patient and provider convenience.
• Strong balance sheet with a cash runway expected into the first half of 2028, supporting ongoing development and commercialization efforts.
• Manufacturing process is high-yielding, scalable, and stable, with distributed partnerships for redundancy, positioning the company for market launch and expansion.

Risks

• Dependence entirely on the success of cretostimogene, which is the only product candidate.
• Potential for delays in the commencement, enrollment, and completion of clinical trials and preclinical studies.
• Results from earlier clinical trials and preclinical studies may not necessarily be predictive of future results.
• Risk of unfavorable results from ongoing or future clinical trials.
• Unexpected adverse side effects or inadequate efficacy of cretostimogene could limit its development, regulatory approval, and/or commercialization.
• Preliminary or interim data results are not necessarily indicative of final results, and clinical outcomes may change with more data.
• Dependence on third parties for manufacturing, shipping, and clinical and preclinical testing.
• Uncertainty regarding regulatory developments in the United States and foreign countries.
• Challenges in obtaining, maintaining, and enforcing intellectual property protection for cretostimogene.
• Capital resources may be used sooner than expected.
• Significant competition in the bladder cancer treatment market.

Future Outlook

CG Oncology plans to deliver on key milestones, including indication expansion and commercialization of cretostimogene. The company anticipates initiating and completing a Biologics License Application (BLA) submission for High-Risk NMIBC as its first indication, followed by a supplemental BLA (sBLA) submission for Intermediate-Risk NMIBC. Ongoing clinical trials (PIVOT-006, CORE-008 cohorts A, B, CX) are expected to expand cretostimogene's use into intermediate-risk, BCG-nave, and BCG-exposed NMIBC populations, as well as combination therapies. The overarching goal is to establish cretostimogene as a backbone therapeutic option for NMIBC.

Management Comments

• "Our Goal is to Establish Cretostimogene as a Backbone Therapeutic Option for NMIBC."
• "We believe CGs experienced commercial team will be able to efficiently address significant share of bladder cancer market."
• "Our Vision: We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life."
• "Our Mission: We are focused on developing bladder-sparing therapeutics for patients afflicted with bladder cancer."

Industry Context

Bladder cancer is a prevalent disease, with over 85,000 new diagnoses annually in the U.S. and more than 730,000 individuals living with it. Non-Muscle Invasive Bladder Cancer (NMIBC) constitutes approximately 75% of new cases, representing a multi-billion dollar market. The disease is characterized by high recurrence rates and a complex treatment journey with suboptimal outcomes, particularly for high-risk patients. Existing standard-of-care treatments like TURBT and BCG have been in use for decades, and there is a significant unmet need for innovative therapies, exacerbated by current BCG shortages. Cretostimogene aims to disrupt this landscape by offering a novel, durable, and well-tolerated treatment option.

Comparison to Industry Standards

• Cretostimogene (BOND-003) demonstrated a 24-month Complete Response (CR) rate of 41.8%, significantly higher than N-803 + BCG (24.7%), Nadofaragene (19.4%), and Pembrolizumab (9.4%).
• The median Duration of Response (DoR) for cretostimogene exceeds 28 months and is ongoing, which is longer than TAR-200 (10 months), N-803 + BCG (26 months), and Nadofaragene (16 months).
• Cretostimogene reported 0% Grade 3+ treatment-related adverse events (TRAEs), a superior safety profile compared to TAR-200 (13%), N-803 + BCG (16% SAE), Nadofaragene (4%), and Pembrolizumab (13%).
• In HR BCG-unresponsive NMIBC Ta/T1 (BOND-003 Cohort P), cretostimogene's 90.5% HG-RFS at 3and 9-month compares favorably against industry benchmarks of approximately 43-55% DFS at 12-month for similar populations.
• Cretostimogene's 96.6% freedom from progression to MIBC at 24 months is comparable to or better than other agents like TAR-200 (94.3%), N-803 + BCG (100%), Nadofaragene (94%), and Pembrolizumab (89%).

Stakeholder Impact

• **Patients:** Potential for a highly effective, durable, and well-tolerated bladder-sparing treatment option for NMIBC, improving quality of life.
• **Shareholders:** Positive clinical data and a clear development pathway could lead to increased shareholder value. The strong cash runway reduces immediate dilution risk.
• **Healthcare Providers (Urologists, Nurses):** The easy administration process that fits existing workflows could simplify treatment delivery and adoption.
• **Regulators (FDA):** Breakthrough Therapy and Fast Track designations indicate recognition of unmet medical need and potential benefit, potentially accelerating review.

Next Steps

• Topline data for BOND-003 Cohort P expected in 4Q25.
• First results for CORE-008 Cohort A expected in 4Q25.
• Data for CORE-008 Cohort B expected in 2026.
• Topline data for CORE-008 Cohort CX expected in 2026.
• Topline data for PIVOT-006 expected in 2027.
• Long-term durability data for BOND-003 Cohort C expected in 2027.
• Durability data for CORE-008 Cohort A expected in 2027.
• Initiation and completion of cretostimogene BLA Submission for HR NMIBC (1st Indication).
• Completion of sBLA Submission for IR NMIBC (2nd Indication).
• Commercialization efforts for cretostimogene.

Key Dates

Recommendation

The filing presents compelling clinical data for cretostimogene, demonstrating superior efficacy (CR rates, DoR) and an exceptionally favorable safety profile compared to existing and investigational therapies for high-risk BCG-unresponsive NMIBC. The product's ease of administration, large market opportunity, and the company's strong cash position into 1H28, coupled with a clear regulatory and commercialization roadmap, suggest significant upside potential. The Breakthrough Therapy and Fast Track designations further de-risk the regulatory pathway. This combination of factors makes it a highly attractive investment.

Keywords

Bladder cancer, NMIBC, Cretostimogene, Oncolytic immunotherapy, Oncology, Clinical trials, FDA approval, Urology, Cancer treatment, Biotechnology, Pharmaceuticals